Lupin has informed that it enclosed a Press Release as regards the Company having entered into an exclusive licensing agreement with l'rom Group Co, a leading pharmaceutical company in Japan for Denosumab bioslmilar for Japan.
The above information is a part of company’s filings submitted to BSE.